NO20076003L - TGF-beta 1 spesifikke antistoffer - Google Patents

TGF-beta 1 spesifikke antistoffer

Info

Publication number: NO20076003L
Authority: NO; Norway
Prior art keywords: tgf; beta; specific antibodies; compositions; methods
Prior art date: 2005-04-22

Application number

NO20076003A

Other languages

English (en)

Norwegian (no)

Inventor

David Matthew Marquis

Jeffry Dean Watkins

Ying Tang

Lihua Huang

Julian Davies

Craig Duane Dickinson

Bryan Edward Jones

Scott William Rowlinson

Peter Edward Vaillancourt

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-22

Filing date

2007-11-21

Publication date

2008-01-22

2007-11-21 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2008-01-22 Publication of NO20076003L publication Critical patent/NO20076003L/no

Links

102000004887 Transforming Growth Factor beta Human genes 0.000 title abstract 2
108090001012 Transforming Growth Factor beta Proteins 0.000 title abstract 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000003153 chemical reaction reagent Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

NO20076003A 2005-04-22 2007-11-21 TGF-beta 1 spesifikke antistoffer NO20076003L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67408205P	2005-04-22	2005-04-22
PCT/US2006/014943 WO2006116002A2 (fr)	2005-04-22	2006-04-20	Compositions de liaison; reactifs connexes

Publications (1)

Publication Number	Publication Date
NO20076003L true NO20076003L (no)	2008-01-22

Family

ID=37192643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20076003A NO20076003L (no)	2005-04-22	2007-11-21	TGF-beta 1 spesifikke antistoffer

Country Status (23)

Country	Link
US (2)	US7619069B2 (fr)
EP (1)	EP1874818B1 (fr)
JP (1)	JP5070200B2 (fr)
KR (1)	KR100978684B1 (fr)
CN (1)	CN101163719A (fr)
AT (1)	ATE505489T1 (fr)
AU (1)	AU2006240056B2 (fr)
BR (1)	BRPI0608376A8 (fr)
CA (1)	CA2607448C (fr)
CY (1)	CY1111518T1 (fr)
DE (1)	DE602006021292D1 (fr)
DK (1)	DK1874818T3 (fr)
EA (1)	EA016038B1 (fr)
ES (1)	ES2361269T3 (fr)
HR (1)	HRP20110334T1 (fr)
IL (1)	IL186775A (fr)
NO (1)	NO20076003L (fr)
PL (1)	PL1874818T3 (fr)
PT (1)	PT1874818E (fr)
RS (1)	RS51845B (fr)
SI (1)	SI1874818T1 (fr)
UA (1)	UA93201C2 (fr)
WO (1)	WO2006116002A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2334330A4 (fr) *	2008-09-29	2013-05-15	Janssen Biotech Inc	Anticorps anti-cd147, procédés, et utilisations
ES2528799T3 (es) *	2008-11-22	2015-02-12	Astute Medical, Inc.	Métodos para el pronóstico de insuficiencia renal aguda
US8685932B2 (en) *	2008-12-16	2014-04-01	Option Pharmaceuticals, Llc	Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
CA3150199C (fr)	2009-01-09	2025-07-22	Seagen Inc	Regimes posologiques hebdomadaires pour des conjugues anticorps anti-cd30 vc-pab-mmae - medicament
WO2012129330A1 (fr)	2011-03-23	2012-09-27	Option Pharmaceutical, Llc	Cytokine ciblée pour le traitement de maladies musculosquelettiques
AU2012261933B2 (en) *	2011-06-03	2017-06-15	Xoma Technology Ltd.	Antibodies specific for TGF-beta
SG11201401360XA (en)	2011-10-25	2014-05-29	Onclave Therapeutics Ltd	Antibody formulations and methods
DK2822592T3 (en)	2012-03-08	2018-10-15	Ludwig Institute For Cancer Res Limited	TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF
US10259626B2 (en)	2012-03-08	2019-04-16	Selig Sealing Products, Inc.	Container sealing member with protected security component and removal tab
PL3489261T3 (pl)	2012-08-24	2021-08-16	The Regents Of The University Of California	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
CA2911514A1 (fr)	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions et procedes de modulation du facteur de croissance
PT3107573T (pt) *	2014-02-19	2019-01-10	Merck Patent Gmbh	Imunoterapia com il-12 visada ao cancro
WO2016115345A1 (fr)	2015-01-14	2016-07-21	The Brigham And Women's Hospital,	Traitement du cancer avec des anticorps monoclonaux anti-lap
TWI726870B (zh) *	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
SG11201805941WA (en)	2016-02-17	2018-09-27	Novartis Ag	Tgfbeta 2 antibodies
AU2017222928A1 (en) *	2016-02-26	2018-09-20	Eli Lilly And Company	Anti-CD11d antibodies and uses thereof
EP4169942A1 (fr) *	2016-03-11	2023-04-26	Scholar Rock, Inc.	Immunoglobulines se liant à tgfbeta1 et leur utilisation
CA3024465A1 (fr)	2016-05-17	2017-11-23	Genentech, Inc.	Signatures genetiques stromales destinees au diagnostic et a l'utilisation en immunotherapie
AU2017268469C1 (en) *	2016-05-20	2025-01-02	President And Fellows Of Harvard College	Gene therapy methods for age-related diseases and conditions
CA3029003A1 (fr)	2016-06-27	2018-01-04	The Regents Of The University Of California	Associations medicamenteuses pour le traitement du cancer
WO2018043734A1 (fr) *	2016-09-05	2018-03-08	Chugai Seiyaku Kabushiki Kaisha	Anticorps anti-tgf-beta 1 et leurs procédés d'utilisation
CN109071656B (zh)	2017-01-05	2021-05-18	璟尚生物制药公司	检查点调节物拮抗剂
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en)	2017-05-02	2019-11-28	Merck Sharp & Dohme	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
WO2019045086A1 (fr) *	2017-08-29	2019-03-07	林化成株式会社	UTILISATION D'UN ANTICORPS SPÉCIFIQUE POUR TGF-β1 ACTIF OU LATENT
EP3694552A1 (fr)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anticorps anti-lap et leurs utilisations
AU2018359967A1 (en)	2017-11-06	2020-04-23	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2020006516A1 (fr)	2018-06-29	2020-01-02	Gensun Biopharma, Inc.	Antagonistes des régulateurs de points de contrôle immunitaires antitumoraux
WO2020076969A2 (fr)	2018-10-10	2020-04-16	Tilos Therapeutics, Inc.	Variants d'anticorps anti-lap et leurs utilisations
EP3876990A4 (fr)	2018-11-07	2023-09-06	Merck Sharp & Dohme LLC	Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EA202192130A1 (ru)	2019-01-30	2021-12-28	Сколар Рок, Инк.	Специфичные к ltbp-комплексу ингибиторы tgf и их применение
WO2020263312A1 (fr)	2019-06-28	2020-12-30	Gensun Biopharma, Inc.	ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFβ1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
JP2023511255A (ja)	2020-01-11	2023-03-17	スカラーロックインコーポレイテッド	ＴＧＦ－β阻害剤及びその使用
CN115190812A (zh)	2020-01-11	2022-10-14	供石公司	TGFβ抑制剂及其用途
WO2022204581A2 (fr)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Inhibiteurs de tgf-bêta et leur utilisation
WO2022256723A2 (fr)	2021-06-03	2022-12-08	Scholar Rock, Inc.	Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
WO2022266510A1 (fr) *	2021-06-18	2022-12-22	Genzyme Corporation	Formulations d'anticorps anti-tgf-bêta et leur utilisation
EP4370148A1 (fr)	2021-07-14	2024-05-22	Scholar Rock, Inc.	Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
WO2023080900A1 (fr)	2021-11-05	2023-05-11	Genentech, Inc.	Procédés et compositions pour classer et traiter le cancer rénal
EP4599089A1 (fr)	2022-10-05	2025-08-13	Genentech, Inc.	Méthodes et compositions de classification et de traitement du cancer de la vessie
EP4599088A1 (fr)	2022-10-05	2025-08-13	Genentech, Inc.	Procédés et compositions pour la classification et le traitement du cancer du poumon
WO2024187051A1 (fr)	2023-03-07	2024-09-12	Scholar Rock, Inc.	Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
WO2025240343A1 (fr)	2024-05-13	2025-11-20	Scholar Rock, Inc.	Inhibiteurs de tgf-bêta pour le traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) *	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
CA2358400C (fr)	1999-01-05	2012-05-15	Nancy A. Noble	Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
US7763580B2 (en) *	1999-01-05	2010-07-27	University Of Utah Research Foundation	Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
WO2004098637A1 (fr)	2003-04-30	2004-11-18	Genzyme Corporation	Antagonistes du tgf-beta combine avec des antagonistes du systeme renine-angiotensine-aldosterone pour le traitement de l'insuffisance renale
EP1646655A2 (fr) *	2003-07-09	2006-04-19	Eli Lilly And Company	Ligands de tgf-beta1
US20070148170A1 (en) *	2005-10-03	2007-06-28	Desjarlais John R	Fc Variants With Optimized Fc Receptor Binding Properties
CA2561686C (fr)	2004-03-31	2014-12-02	Genentech, Inc.	Anticorps anti-tgf-beta humanises
AU2005251764A1 (en)	2004-06-04	2005-12-22	Genentech, Inc.	Method for treating lupus

2006
- 2006-04-20 ES ES06750860T patent/ES2361269T3/es active Active
- 2006-04-20 CN CNA2006800135110A patent/CN101163719A/zh active Pending
- 2006-04-20 RS RS20110195A patent/RS51845B/sr unknown
- 2006-04-20 PL PL06750860T patent/PL1874818T3/pl unknown
- 2006-04-20 WO PCT/US2006/014943 patent/WO2006116002A2/fr not_active Ceased
- 2006-04-20 HR HR20110334T patent/HRP20110334T1/hr unknown
- 2006-04-20 DK DK06750860.6T patent/DK1874818T3/da active
- 2006-04-20 EP EP06750860A patent/EP1874818B1/fr active Active
- 2006-04-20 AT AT06750860T patent/ATE505489T1/de active
- 2006-04-20 DE DE602006021292T patent/DE602006021292D1/de active Active
- 2006-04-20 EA EA200702278A patent/EA016038B1/ru not_active IP Right Cessation
- 2006-04-20 AU AU2006240056A patent/AU2006240056B2/en not_active Ceased
- 2006-04-20 JP JP2008507883A patent/JP5070200B2/ja not_active Expired - Fee Related
- 2006-04-20 SI SI200631049T patent/SI1874818T1/sl unknown
- 2006-04-20 KR KR1020077024149A patent/KR100978684B1/ko not_active Expired - Fee Related
- 2006-04-20 CA CA2607448A patent/CA2607448C/fr not_active Expired - Fee Related
- 2006-04-20 BR BRPI0608376A patent/BRPI0608376A8/pt not_active IP Right Cessation
- 2006-04-20 UA UAA200711364A patent/UA93201C2/ru unknown
- 2006-04-20 PT PT06750860T patent/PT1874818E/pt unknown
2007
- 2007-10-18 IL IL186775A patent/IL186775A/en not_active IP Right Cessation
- 2007-10-19 US US11/874,952 patent/US7619069B2/en not_active Expired - Fee Related
- 2007-11-21 NO NO20076003A patent/NO20076003L/no not_active Application Discontinuation
2009
- 2009-10-15 US US12/579,447 patent/US8128927B2/en not_active Expired - Fee Related
2011
- 2011-05-13 CY CY20111100455T patent/CY1111518T1/el unknown

Also Published As

Publication number	Publication date
IL186775A0 (en)	2008-02-09
RS51845B (sr)	2012-02-29
ATE505489T1 (de)	2011-04-15
HRP20110334T1 (hr)	2011-06-30
WO2006116002A2 (fr)	2006-11-02
WO2006116002A3 (fr)	2007-02-01
PT1874818E (pt)	2011-05-05
US20100040633A1 (en)	2010-02-18
JP2008538564A (ja)	2008-10-30
BRPI0608376A2 (pt)	2010-11-16
CA2607448A1 (fr)	2006-11-02
CN101163719A (zh)	2008-04-16
ES2361269T3 (es)	2011-06-15
EA016038B1 (ru)	2012-01-30
BRPI0608376A8 (pt)	2018-10-16
CA2607448C (fr)	2014-11-18
EA200702278A1 (ru)	2008-08-29
DK1874818T3 (da)	2011-06-14
UA93201C2 (ru)	2011-01-25
AU2006240056B2 (en)	2012-02-16
KR100978684B1 (ko)	2010-08-31
EP1874818A2 (fr)	2008-01-09
KR20070114220A (ko)	2007-11-29
AU2006240056A1 (en)	2006-11-02
IL186775A (en)	2013-03-24
US8128927B2 (en)	2012-03-06
US20080050375A1 (en)	2008-02-28
EP1874818B1 (fr)	2011-04-13
WO2006116002A9 (fr)	2007-07-19
CY1111518T1 (el)	2015-08-05
JP5070200B2 (ja)	2012-11-07
PL1874818T3 (pl)	2011-09-30
DE602006021292D1 (de)	2011-05-26
US7619069B2 (en)	2009-11-17
SI1874818T1 (sl)	2011-08-31

Publication	Publication Date	Title
NO20076003L (no)	2008-01-22	TGF-beta 1 spesifikke antistoffer
CY1124802T1 (el)	2022-11-25	Δεσμευτικοι παραγοντες σκληροστινης
MY174493A (en)	2020-04-23	Binding agents
CY2018013I2 (el)	2018-09-05	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1121208T1 (el)	2020-05-29	Σκευασματα αντισωματος ναταλιζουμαμπης
CY1113199T1 (el)	2016-04-13	Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EA200970210A1 (ru)	2009-08-28	Prlr-специфическое антитело и его применения
NO20083397L (no)	2008-10-02	Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE548374T1 (de)	2012-03-15	2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
DK3530673T3 (da)	2022-04-19	Humaniserede anti-beta7-antagonister og anvendelser deraf
MEP35408A (en)	2011-02-10	Tweak binding antibodies
CY1116261T1 (el)	2017-02-08	Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
EP1799260A4 (fr)	2011-09-28	Anticorps anti- amyloide, compositions, techniques et utilisations
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
NO20081287A (no)	2008-05-06	Brenselsammensetning og fremgangsmåte for å fremstille denne
NO20082240L (no)	2008-07-22	GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
CY1113309T1 (el)	2016-04-13	Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
DK1817055T3 (da)	2013-04-08	Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
NO20083609L (no)	2008-11-12	Fremgangsmater og sammensetninger for malrettet-RELT
MX2007013108A (es)	2008-04-07	Reactivos que enlazan ccx-ckr2.
HK1151803B (en)	2015-08-28	Sclerostin binding agents

Legal Events

Date	Code	Title	Description
2018-04-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application